0EE0 Stock Overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.73 |
| 52 Week High | US$22.20 |
| 52 Week Low | US$4.62 |
| Beta | 0.95 |
| 1 Month Change | -8.69% |
| 3 Month Change | -17.45% |
| 1 Year Change | -76.26% |
| 3 Year Change | -86.36% |
| 5 Year Change | -91.24% |
| Change since IPO | -75.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0EE0 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.4% | -1.9% | -0.9% |
| 1Y | -76.3% | -30.5% | -1.8% |
Return vs Industry: 0EE0 underperformed the UK Biotechs industry which returned -30.5% over the past year.
Return vs Market: 0EE0 underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0EE0 volatility | |
|---|---|
| 0EE0 Average Weekly Movement | 8.4% |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0EE0's share price has been volatile over the past 3 months.
Volatility Over Time: 0EE0's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 480 | Matt Kapusta | www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
uniQure N.V. Fundamentals Summary
| 0EE0 fundamental statistics | |
|---|---|
| Market cap | US$233.73m |
| Earnings (TTM) | -US$308.48m |
| Revenue (TTM) | US$15.84m |
14.8x
P/S Ratio-0.8x
P/E RatioIs 0EE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0EE0 income statement (TTM) | |
|---|---|
| Revenue | US$15.84m |
| Cost of Revenue | US$212.60m |
| Gross Profit | -US$196.75m |
| Other Expenses | US$111.72m |
| Earnings | -US$308.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.36 |
| Gross Margin | -1,241.90% |
| Net Profit Margin | -1,947.09% |
| Debt/Equity Ratio | 238.8% |
How did 0EE0 perform over the long term?
See historical performance and comparison